Adult Solid Tumor Clinical Trial
Official title:
An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors
The purpose of the study is to evaluate safety and tolerability and determine a recommended Phase 2 dose for TRC105 when added to standard dose bevacizumab in patients with advanced solid tumors for which bevacizumab is indicated.
Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) that inhibits angiogenesis and extends survival in patients with a wide variety of solid tumor types. TRC105, a monoclonal antibody to CD105, is a novel angiogenesis inhibitor that complements bevacizumab in preclinical models. Together, these antibodies may result in more effective angiogenesis inhibition and improved clinical efficacy over that seen with bevacizumab alone. The purpose of the study is to evaluate safety and tolerability and determine a recommended Phase 2 dose for TRC105 when added to standard dose bevacizumab in patients with advanced solid tumors for which bevacizumab is indicated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04538625 -
Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
|
Phase 3 | |
| Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
| Recruiting |
NCT06403436 -
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03061305 -
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
|
||
| Active, not recruiting |
NCT02568267 -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
|
Phase 2 | |
| Terminated |
NCT05357898 -
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06277804 -
A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor
|
Phase 1 | |
| Completed |
NCT03818347 -
Hydrogen Gas for Cancer Rehabilitation
|
N/A | |
| Completed |
NCT05400265 -
Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor
|
Phase 1 | |
| Recruiting |
NCT04705818 -
Combining Epigenetic And Immune Therapy to Beat Cancer.
|
Phase 2 | |
| Completed |
NCT01269918 -
A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
|
N/A | |
| Suspended |
NCT03253575 -
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
|
||
| Completed |
NCT04084951 -
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT03760952 -
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
|
||
| Active, not recruiting |
NCT03445858 -
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
|
Early Phase 1 | |
| Completed |
NCT03303365 -
Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence
|
N/A | |
| Not yet recruiting |
NCT05666635 -
Study of LTC004 in Subjects With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05752552 -
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
|
Phase 1 | |
| Active, not recruiting |
NCT05147272 -
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
|
Phase 1 |